Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Vanessa, Burhenne, Jürgen, Weiss, Johanna, Haag, Mathias, Hofmann, Ute, Schwab, Matthias, Urban, Stephan, Mikus, Gerd, Czock, David, Haefeli, Walter E., Blank, Antje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117888/
https://www.ncbi.nlm.nih.gov/pubmed/37089922
http://dx.doi.org/10.3389/fphar.2023.1128547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117888/
https://www.ncbi.nlm.nih.gov/pubmed/37089922
http://dx.doi.org/10.3389/fphar.2023.1128547

Ejemplares similares